Efficacy of leuprolide therapy in children with central precocious puberty.

Abstract

Eight girls with central precocious puberty were treated with the long-acting gonadotropin releasing hormone analogue leuprolide acetate (Lupron) for a period of six to 18 months. Suppression of gonadotropin and estradiol secretion and regression of secondary sexual characteristics and menses were observed while patients received a subcutaneous dose of 35 to 40 micrograms/kg/d. Growth velocity was slowed in all but one patient, and the rate of skeletal maturation was slowed even more, resulting in a stabilization or improvement in predicted adult height. There were no major side effects. Although the long-term effects of leuprolide therapy cannot be determined with this study, it appears to be efficacious in the treatment of central precocious puberty.

• Authors: M S Kappy, T Stuart, A Perelman
• Journal: American journal of diseases of children (1960) (Am J Dis Child) Vol. 142 Issue 10 Pg. 1061-4 (Oct 1988) ISSN: 0002-922X [Print] United States
• PMID: 3140654 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Gonadotropin-Releasing Hormone
• Estradiol
• Luteinizing Hormone
• Follicle Stimulating Hormone
• Leuprolide

Topics

• Age Determination by Skeleton
• Child
• Child, Preschool
• Estradiol (blood)
• Female
• Follicle Stimulating Hormone (blood)
• Gonadotropin-Releasing Hormone (adverse effects, analogs & derivatives, therapeutic use)
• Growth
• Humans
• Leuprolide
• Luteinizing Hormone (blood)
• Puberty, Precocious (blood, drug therapy, physiopathology)